Laugier P, Orusco M
Curr Med Res Opin. 1978;5(5):371-5. doi: 10.1185/03007997809111900.
Forty patients suffering from a dermatological condition suitable for treatment with an antihistamine were studied in a double-blind randomized trial to compare the effectiveness and tolerance of mequitazine and placebo. Over a period of 2 weeks, patients received either 5 mg mequitazine twice daily or placebo. Where justified, patients were also given concomitant topical treatment but only with a hydrating cream or ichthyol paste. Patients' overall response to treatment was significantly better in the mequitazine group, whether the results were analyzed for all patients or those receiving just the trial drugs without topical treatment. Few side-effects were reported and there was no significant difference between the levels of drowsiness experienced with mequitazine compared with placebo.
在一项双盲随机试验中,对40名患有适合用抗组胺药治疗的皮肤病患者进行了研究,以比较美喹他嗪和安慰剂的有效性及耐受性。在为期2周的时间里,患者每日两次服用5毫克美喹他嗪或安慰剂。在合理的情况下,患者还接受了辅助局部治疗,但仅限于使用保湿霜或鱼石脂软膏。无论对所有患者进行分析,还是对仅接受试验药物而未接受局部治疗的患者进行分析,美喹他嗪组患者对治疗的总体反应均显著更好。报告的副作用很少,与安慰剂相比,服用美喹他嗪时出现的嗜睡程度没有显著差异。